S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
OTCMKTS:EMMA

Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

$0.11
0.00 (0.00%)
(As of 04/17/2024 ET)
Today's Range
$0.11
$0.11
50-Day Range
$0.09
$0.13
52-Week Range
$0.05
$0.35
Volume
41 shs
Average Volume
2,782 shs
Market Capitalization
$7.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
EMMA stock logo

About Emmaus Life Sciences Stock (OTCMKTS:EMMA)

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

EMMA Stock Price History

EMMA Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Emmaus Life Sciences Inc (EMMA)
Emmaus Life Sciences Inc.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Emmaus Life Sciences Reports Q3 2023 Financial Results
See More Headlines
Receive EMMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:EMMA
Employees
54
Year Founded
N/A

Profitability

Net Income
$-10,620,000.00
Pretax Margin
-16.42%

Debt

Sales & Book Value

Annual Sales
$18.39 million
Book Value
($0.69) per share

Miscellaneous

Free Float
40,200,000
Market Cap
$7.04 million
Optionable
Not Optionable
Beta
1.61
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Willis C. Lee M.S. (Age 64)
    Co-President, COO & Chairman of the Board
    Comp: $240k
  • Mr. Yasushi Nagasaki CPA (Age 57)
    CPA, Chief Financial Officer
    Comp: $250k
  • Mr. George Sekulich (Age 58)
    Co-President, Chief Commercial Officer & Director
  • Mr. Dale E. Short J.D.
    Legal Consultant & Corporate Secretary
  • Dr. Charles W. Stark Pharm.D (Age 69)
    Pharm.D., Senior Vice President of Medical Affairs, Clinical, Regulatory
  • Mr. Kurt H. Kruger M.B.A. (Age 69)
    M.S., Consultant
    Comp: $300.02k

EMMA Stock Analysis - Frequently Asked Questions

How have EMMA shares performed in 2024?

Emmaus Life Sciences' stock was trading at $0.1001 on January 1st, 2024. Since then, EMMA stock has increased by 13.6% and is now trading at $0.1138.
View the best growth stocks for 2024 here
.

Are investors shorting Emmaus Life Sciences?

Emmaus Life Sciences saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 800 shares, a drop of 89.5% from the March 15th total of 7,600 shares. Based on an average trading volume of 12,400 shares, the short-interest ratio is currently 0.1 days.
View Emmaus Life Sciences' Short Interest
.

How do I buy shares of Emmaus Life Sciences?

Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EMMA) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners